| Title: |
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial |
| Authors: |
Colhoun, HM; Lingvay, I; Brown, PM; Deanfield, J; Brown-Frandsen, K; Kahn, SE; Plutzky, J; Node, K; Parkhomenko, A; Rydén, L; Wilding, JPH; Mann, JFE; Tuttle, KR; Idorn, T; Rathor, N; Lincoff, AM |
| Publisher Information: |
Springer Science and Business Media LLC |
| Publication Year: |
2024 |
| Collection: |
The University of Liverpool Repository |
| Description: |
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min −1 1.73 m − 2 , persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min −1 1.73 m − 2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min −1 1.73 m − 2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
1078-8956 |
| Relation: |
Collapse authors list. Colhoun, HM orcid:0000-0002-8345-3288 , Lingvay, I orcid:0000-0001-7006-7401 , Brown, PM, Deanfield, J, Brown-Frandsen, K, Kahn, SE, Plutzky, J orcid:0000-0002-7194-9876 , Node, K orcid:0000-0002-2534-0939 , Parkhomenko, A orcid:0000-0002-3563-9627 , Rydén, L et al (show 6 more authors) , Wilding, JPH orcid:0000-0003-2839-8404 , Mann, JFE, Tuttle, KR orcid:0000-0002-2235-0103 , Idorn, T, Rathor, N and Lincoff, AM orcid:0000-0001-8175-2121 (2024) Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial Nature Medicine, 30 (7). pp. 2058-2066. ISSN 1078-8956, 1546-170X |
| DOI: |
10.1038/s41591-024-03015-5 |
| Availability: |
https://livrepository.liverpool.ac.uk/3183273/; https://doi.org/10.1038/s41591-024-03015-5 |
| Accession Number: |
edsbas.61ED94E2 |
| Database: |
BASE |